Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Date: September 30, 2016
Pages: 111
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M7071D8D680EN
Leaflet:

Download PDF Leaflet

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016
Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016’, provides an overview of the Mitsubishi Tanabe Pharma Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Mitsubishi Tanabe Pharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Mitsubishi Tanabe Pharma Corporation
  • The report provides overview of Mitsubishi Tanabe Pharma Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Mitsubishi Tanabe Pharma Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Mitsubishi Tanabe Pharma Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Mitsubishi Tanabe Pharma Corporation’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mitsubishi Tanabe Pharma Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitsubishi Tanabe Pharma Corporation’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Mitsubishi Tanabe Pharma Corporation Snapshot
Mitsubishi Tanabe Pharma Corporation Overview
Key Facts
Mitsubishi Tanabe Pharma Corporation - Research and Development Overview
Key Therapeutic Areas
Mitsubishi Tanabe Pharma Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance
Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products
IND/CTA Filed Products/Combination Treatment Modalities
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation - Drug Profiles
(canagliflozin + teneligliptin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amiselimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bepotastine besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canagliflozin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cariprazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edaravone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fingolimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-1057 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masilukast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIN-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Inflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-0814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-3995 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-4580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-7117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-8554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-3404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teneligliptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valbenazine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Y-320 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action
Mitsubishi Tanabe Pharma Corporation - Dormant Projects
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AMG-899
AV-412
caldaret
carmoterol
coleneuramide
colestilan chloride
ecabet
edaravone
encenicline hydrochloride
fingolimod hydrochloride
immune globulin (human)
marimastat
masilukast
MP-136
MP-435
MT-7716
netoglitazone
sofigatran
TA-5493
TA-5538
TA-6666
TAK-128
telaprevir
Y-700
Mitsubishi Tanabe Pharma Corporation - Company Statement
Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Mitsubishi Tanabe Pharma Corporation, Key Facts
Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2016
Mitsubishi Tanabe Pharma Corporation - Phase III, 2016
Mitsubishi Tanabe Pharma Corporation - Phase II, 2016
Mitsubishi Tanabe Pharma Corporation - Phase I, 2016
Mitsubishi Tanabe Pharma Corporation - IND/CTA Filed, 2016
Mitsubishi Tanabe Pharma Corporation - Preclinical, 2016
Mitsubishi Tanabe Pharma Corporation - Discovery, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2016
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2016
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2016
Mitsubishi Tanabe Pharma Corporation, Other Locations
Mitsubishi Tanabe Pharma Corporation, Subsidiaries

LIST OF FIGURES

Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Indication, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2016
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Target, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2016
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Ask Your Question

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: